Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients

Pediatric Transplantation

Volumn 6, Issue 2, 2002, Pages 147-152

  VanDamme Lombaerts, R ^a   Webb, N ^b   Hoyer, P F ^c   Mahan, J ^d   Lemire, J ^e   Ettenger, R ^f   McMahon, L ^g   Cambon, N ^g   Boger, R ^g   Kovarik, J M ^g  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Everolimus; Pediatric renal transplantation; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS;

ADOLESCENT; ARTICLE; BODY SIZE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; STEADY STATE;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 0036246092     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2002.01070.x     Document Type: Article

References (19)

1. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
2. Chemical modification of rapamycin: The discovery of SDZ RAD
3. Rapamune (sirolimus, rapamycin): An overview and mechanism of action
4. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation
5. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model
6. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine
7. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection
8. Growth after renal transplantation: Correlation with immunosuppressive therapy
9. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506)
10. 15 years of pediatric heart transplantation at the University of Pittsburgh: Lessons learned and future prospects
11. Steady improvement in renal allograft survival among North American children: A five year appraisal by the North American Pediatric Renal Transplant Cooperative Study
12. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients
13. A phase 1 study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporineprednisone-treated renal transplant recipients
14. Sirolimus: A new agent for prevention of renal allograft rejection
15. The potential role of rapamycin in pediatric transplantation as observed from adult studies
16. Sirolimus pharmacokinetics in pediatric renal transplants
17. Cyclosporin A (Neoral®) in pediatric organ transplantation
18. Pharmacokinetics of a new microemulsion formulation of cyclosporin A (Neoral®) in young patients after renal transplantation